ZA201101891B - The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide - Google Patents

The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide

Info

Publication number
ZA201101891B
ZA201101891B ZA2011/01891A ZA201101891A ZA201101891B ZA 201101891 B ZA201101891 B ZA 201101891B ZA 2011/01891 A ZA2011/01891 A ZA 2011/01891A ZA 201101891 A ZA201101891 A ZA 201101891A ZA 201101891 B ZA201101891 B ZA 201101891B
Authority
ZA
South Africa
Prior art keywords
cyanocyclopentyl
pyridinecarboxamide
phenyl
salts
amino
Prior art date
Application number
ZA2011/01891A
Other languages
English (en)
Inventor
Kaihong Yuan
Piaoyang Sun
Yunshu Zhou
Yongjiang Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of ZA201101891B publication Critical patent/ZA201101891B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA2011/01891A 2008-09-16 2011-03-11 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide ZA201101891B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2008101496511A CN101676267B (zh) 2008-09-16 2008-09-16 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
PCT/CN2009/072239 WO2010031266A1 (zh) 2008-09-16 2009-06-11 N-[4-(1-氰基环戊基)苯基]-2-（4-吡啶甲基）氨基-3-吡啶甲酰胺的盐

Publications (1)

Publication Number Publication Date
ZA201101891B true ZA201101891B (en) 2012-05-30

Family

ID=42029001

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/01891A ZA201101891B (en) 2008-09-16 2011-03-11 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide

Country Status (12)

Country Link
US (1) US8362256B2 (enExample)
EP (1) EP2327697B1 (enExample)
JP (1) JP5649132B2 (enExample)
KR (1) KR101674227B1 (enExample)
CN (1) CN101676267B (enExample)
AU (1) AU2009295168B2 (enExample)
BR (1) BRPI0919018A2 (enExample)
CA (1) CA2736664C (enExample)
MX (1) MX2011002816A (enExample)
RU (1) RU2499796C2 (enExample)
WO (1) WO2010031266A1 (enExample)
ZA (1) ZA201101891B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072412A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用
CN104086483A (zh) * 2014-07-08 2014-10-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用
CN104072413A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用
CN104072410B (zh) * 2014-07-08 2017-02-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用
CN104086484B (zh) * 2014-07-08 2016-05-25 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用
CN104072411A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用
CN105622498A (zh) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
CN105622499A (zh) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
CN105541708A (zh) * 2014-10-28 2016-05-04 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
EP3283560B1 (en) 2015-04-15 2019-11-13 Dow Global Technologies LLC Thermally insulating foam with vertically elongated cells
CN105801476A (zh) * 2016-04-13 2016-07-27 上海宣创生物科技有限公司 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用
CN106243031B (zh) * 2016-07-26 2017-09-08 江苏恒瑞医药股份有限公司 一种阿帕替尼的制备方法
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
TWI771344B (zh) 2016-12-01 2022-07-21 大陸商江蘇恆瑞醫藥股份有限公司 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
CN108250138A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼a晶型及其制备方法和应用
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
CN109381436A (zh) * 2017-08-14 2019-02-26 江苏恒瑞医药股份有限公司 阿帕替尼药物组合物及其制备方法
CN109394685B (zh) * 2017-08-15 2021-04-06 江苏恒瑞医药股份有限公司 一种vegfr抑制剂的药物组合物及其制备方法
CN110637010A (zh) * 2017-08-15 2019-12-31 江苏恒瑞医药股份有限公司 一种vegfr抑制剂晶型及其制备方法
EP3706746A4 (en) * 2017-11-10 2021-12-15 Elevar Therapeutics, Inc. COMBINATION THERAPY WITH APATINIB FOR TREATMENT OF CANCER
MX2020005659A (es) 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Co Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
CN109942487A (zh) * 2017-12-21 2019-06-28 江苏恒瑞医药股份有限公司 一种吡啶类化合物及其制备方法、用途
JP2021508699A (ja) 2017-12-29 2021-03-11 江蘇恒瑞医薬股▲ふん▼有限公司 トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用
US11434202B2 (en) 2018-09-05 2022-09-06 Assia Chemical Industries Ltd. Crystalline polymorphs of Rivoceranib and Rivoceranib mesylate
CN115279405B (zh) * 2020-04-10 2025-02-18 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
AU2003281855A1 (en) * 2002-07-31 2004-02-23 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
CN1281590C (zh) * 2002-11-27 2006-10-25 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
RU2499796C2 (ru) 2013-11-27
US20110184023A1 (en) 2011-07-28
BRPI0919018A2 (pt) 2015-12-08
EP2327697B1 (en) 2014-03-12
JP2012502885A (ja) 2012-02-02
CN101676267B (zh) 2012-12-26
MX2011002816A (es) 2011-04-05
HK1141514A1 (en) 2010-11-12
US8362256B2 (en) 2013-01-29
JP5649132B2 (ja) 2015-01-07
AU2009295168B2 (en) 2014-02-13
WO2010031266A1 (zh) 2010-03-25
CN101676267A (zh) 2010-03-24
RU2011113229A (ru) 2012-10-27
CA2736664A1 (en) 2010-03-25
EP2327697A4 (en) 2012-06-06
KR20110059877A (ko) 2011-06-07
AU2009295168A1 (en) 2010-03-25
CA2736664C (en) 2016-05-24
EP2327697A1 (en) 2011-06-01
KR101674227B1 (ko) 2016-11-08

Similar Documents

Publication Publication Date Title
IL248124B (en) 5,3-diamino-6-chloro-n-(-n(4-(4-(2-(hexyl (6,5,4,3,2-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine -2-carboxamide
IL253119A0 (en) 4-{4[({[4-chloro-3-(trifluoroacetyl)phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate and preparations including it
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
IL197369A0 (en) 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}
AP2013007233A0 (en) l)-3-(trifluoromethyl phenylÜ benzamide solubilizeModified release of 4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-N-5-(4-methyl-IH-imidazol-I-yd using organic acids
IL242279A0 (en) Compounds of 3-chloro-3]-n-(pyrimidine-2-ylamino)phenyl]substituted propanamide and their salts
ZA201102732B (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
ZA201105262B (en) Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxo-butyric acid amide as kcnq2/3 modulators
DK1968949T3 (da) Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider
WO2013150545A8 (en) Process for preparation of benzimidazole derivatives and salts thereof
SMT201200026B (it) Polimorfo B di N-(2-amminofenil)-4-[N-(piridin-3-il)-metossicarbonilamminometil]-benzamide (MS-275)
IL243913A0 (en) 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ylsulfonylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
ZA201402756B (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation
PL2279178T3 (pl) 2-(podstawione-fenylo)-6-hydroksy- lub alkoksy-5-podstawione-4 pirymidynokarboksylany i ich zastosowanie jako herbicydów
IL209197A0 (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
SI2608789T2 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
PL2943488T3 (pl) Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1
SI2358680T1 (sl) Trdne obllike n-(4-(7-azabiciklo(2.2.1)heptan-7-il)-2-(trifluorometil) fenil)-4-okso-5-(trifluorometil)-1,4-dihidrokinolin-3-karboksamida
HK1193102A (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids